Teijin Pharma Limited

Mika Takakuwa

Hiroaki Makino

Kenichiro Kataoka

Gen Unoki

Tomomi Kosugi

Yuko Yamakoshi

Minoru Imai

Joelle Le

Satoshi Sugiura

Yoshiyuki Matsumoto

Dale Mitchell

Donald James Simpson

Naotaka Suzuki

Yasuhiro Oue

James Donald Simpson

John Clifford Harris

Yohei Matsueda

Clifford John Harris

Motoko Hamada

Aiko Fujino

Robert Dale Mitchell

The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent MAPKAP-K2 inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for MAPKAP-K2 mediated disorder, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth. 

Pyrazolo[1,5-a]pyrimidine derivatives

The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent kinase inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for a protein kinase mediated disorder in which kinase is implicated, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth. 

Pyrazolo[1,5-A] pyrimidine derivatives

A pyrazolopyrimidine derivative represented by formula (1) and pharmaceutically acceptable salt thereof exhibit excellent inhibitory activity against MAPKAP-K2. Accordingly, medicines containing this compound as an active ingredient are expected to be effective for treating diseases mediated by MAPKAP-K2 such as, for example, inflammatory disorder, autoimmune diseases, destructive osteopathy, cancer and/or tumor growth. 

Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof

A pyrazolo[1,5-a]pyridine derivative represented by formula (I) and salt thereof exhibit excellent MAPKAP-K2 inhibitory activity. Accordingly, medicines comprising this compound as an active ingredient are expected to be valuable for treating or preventing diseases mediated by MAPKAP-K2 such as inflammatory injury, autoimmune diseases, asteropathia destruens, cancer and/or growth of tumor. 

Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof

Growing community of inventors

Tokyo, Japan

Mika Takakuwa